Kidney Transplantation from Anti-HBc+ Donors: Results from a Retrospective Italian Study

Feo, Tullia Maria De; Grossi, Paolo; Poli, Francesca; Mozzi, Fulvio; Minetti, Enrico; Boschiero, L.; Rigotti, Paolo; Maresca, C; Rolla, Davide; Chiaramonte, S.; Gotti, Eliana; Caldara, Rossana; Briano, Giulio; Scalamogna, M.

doi:10.1097/01.tp.0000189930.89031.1b

Cited by 39 publications

(24 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of kidney, heart or lung allocation from an HBsAg-negative/anti-core positive/antiHBs-positive or negative donor in a HBsAg-negative recipient, the risk of hepatitis B appears to be less than 5%. 27,29 The low risk does not justify preventive prophylaxis, but only HBsAg monitoring (every 3-6 months and/or in the case of transaminase increase) and the use of targeted prophylaxis or therapy only in the case of sero-reversion. In analogy to what has been signaled before the risk connected with the use of anti-core positive organs is further reduced by the indications reported in Section "General recommendations in HSCT".…”

Section: Recommendations In Relation To Transplant Donorsmentioning

confidence: 97%

“…Anti-core recipient. In HBsAg-negative and anti-corepositive recipients of kidney, heart and lung transplant the presence of subclinical manifestations (low levels of circulating HBV DNA detectable with amplifi ed techniques post-transplant) without sero-reversion in over 95% of cases 19,23,24,27 has been indicated.…”

Section: Clinical Experiences In Nephrologymentioning

confidence: 98%

“…Finally, the risk of sero-reversion postsurgery (de-novo hepatitis B) in HBsAg-negative/anti-core recipients seems to be lower than 5%. [25][26][27] …”

Section: Dialysis and Solid Organs Transplants (Kidney Heart And Lunmentioning

confidence: 98%

See 2 more Smart Citations

Prophylaxis and treatment of Hepatitis B in immunocompromised patients

2008

View full text Add to dashboard Cite

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and refers mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the treatment with antivirals (therapy) of active carriers, c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg-negative and antiHBc-positive), in order to prevent reverse seroconversion.Moreover it is suggested a strict adherence to the criteria of allocation based on the virological characteristics of both recipients and donors in the general setting of transplants, and in liver transplantation the universal prophylaxis with nucleos(t) ides analogues (frequently combined with specific anti-HBV REVIEW ARTICLE24 immunoglobulins) in HBsAg-positive candidates and in HBsAgnegative recipients of antiHBc-positive grafts should be adopted.

show abstract

Section: Recommendations In Relation To Transplant Donorsmentioning

confidence: 97%

Section: Clinical Experiences In Nephrologymentioning

confidence: 98%

See 1 more Smart Citation

Prophylaxis and treatment of Hepatitis B in immunocompromised patients

2008

View full text Add to dashboard Cite

show abstract

“…In this setting the evolution of the HBV-related disease is accelerated in active carriers and the risk of hepatitis B reactivation post-transplant is over 50% in originally inactive subjects. Finally, the risk of sero-reversion postsurgery (de-novo hepatitis B) in HbsAg-negative/anti-HBc positive recipients seems to be lower than 5%25–27.…”

Section: Dialysis and Solid Organs Transplants (Kidney Heart And Lung)mentioning

confidence: 96%

Management of HBV Infection During Immunosuppresive Treatment

Marzano¹

2009

Medit J Hemat Infect Dis

View full text Add to dashboard Cite

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and refers mainly to the pre-antivirals era. Currently, a rational approach to the problem of hepatitis B in these patients provides for: a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), b) the treatment with antivirals (therapy) of active carriers, c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, d) the biochemical and HBsAg monitoring (or universal prophylaxis in case of high risk immunosuppression, as in onco-haematologic patients and bone marrow transplantation) in subjects with markers of previous contact with HBV (HBsAg-negative and antiHBc-positive), in order to prevent reverse seroconversion. Moreover in solid organ transplants it is suggested a strict adherence to the criteria of allocation based on the virological characteristics of both recipients and donors and the universal prophylaxis or therapy with nucleos(t)ides analogs

show abstract

“…Of 10 publications, there were nine unique studies. 75,77,78,84,[87][88][89][90][91][92] Studies measured virus transmission in 13 different ways (i.e., assays used to detect HBV) with results ranging from 0% to 55%. Transmission rates were likely underreported in some of the studies, as the use of prophylaxis can result in negative recipient testing despite transmission.…”

Section: Q2a Hbv Transmission From Liver Transplantationmentioning

confidence: 99%